The role of myeloperoxidase in HDL oxidation and atherogenesis Jay W. Heinecke Invited Commentary 26 June 2007 Pages: 249 - 251
The strengths and limitations of the ApoB/ApoA-I ratio to predict the risk of vascular disease: a hegelian analysis Allan D. SnidermanRobert S. Kiss OriginalPaper 26 June 2007 Pages: 261 - 265
Atherosclerosis regression: Is low-density lipoprotein or high-density lipoprotein the answer? Stephen J. NichollsE. Murat TuzcuSteven E. Nissen OriginalPaper 26 June 2007 Pages: 266 - 273
Atherosclerosis and cardiovascular risk reduction with PPAR agonists Johanna KuusistoLaura AndrulionyteMarkku Laakso OriginalPaper 26 June 2007 Pages: 274 - 280
Antiatherosclerotic effects of statins: LDL versus non-LDL effects Andrew P. Selwyn OriginalPaper 26 June 2007 Pages: 281 - 285
Lipid goals in metabolic syndrome and diabetes Helen M. Colhoun OriginalPaper 26 June 2007 Pages: 286 - 295
Current management of symptomatic intracranial stenosis: Medical versus endovascular therapy John B. WeigeleRobert A. TaylorScott E. Kasner OriginalPaper 26 June 2007 Pages: 296 - 304
Antiplatelet therapy for stroke prevention Graeme J. Hankey OriginalPaper 26 June 2007 Pages: 312 - 318
Cryptogenic stroke in patients with patent foramen ovale Jeffrey L. Saver OriginalPaper 26 June 2007 Pages: 319 - 325
Diagnosis and management of vascular cognitive impairment David L. NyenhuisPhilip B. Gorelick OriginalPaper 26 June 2007 Pages: 326 - 332
Carotid endarterectomy versus angioplasty/stenting for carotid stenosis Kevin M. BarrettThomas G. Brott OriginalPaper 26 June 2007 Pages: 333 - 340